Bajaj Broking Research desk initiates coverage on Fortis Healthcare with a BUY rating, supported by multi-year visibility in growth, profitability, and balance sheet strengthening. With a ~ 2,000-bed expansion pipeline through FY26–FY29, improving ARPOB and occupancy, and a diagnostics business in margin recovery, Fortis is positioned for one of the strongest earnings upcycles in the healthcare space. SEBI’s approval of the IHH Healthcare open offer removes a long-standing regulatory overhang and reinforces promoter commitment, strengthening governance stability and providing greater clarity on the company’s long-term strategic direction. Fortis enters the growth cycle with conservative leverage and is expected to turn net debt-free by FY28, enhancing financial flexibility for pursuing further expansion plans.
Metric | Value |
Exchange | NSE/BSE – FORTIS / 532843 |
CMP | ₹925 |
Upside | 14% |
Target Price | ₹1,051 |
Bloomberg Code | FORH:IN |
52-Week High / Low | ₹1,105 / ₹521 |
Market Cap | ₹69,849 crore |
Fortis plans to add ~900 beds in FY26, ~600 in FY27, and ~600 in FY28, predominantly via brownfield expansion across FMRI, Mohali, Amritsar, Noida, Faridabad, and Manesar. Owned operational beds rose from 4,024 in FY25 to ~6,124 by FY28, materially expanding network coverage.
The O&M portfolio will also scale meaningfully in FY26 with the onboarding of Gleneagles (700 beds) and Ekana Lucknow (550 beds), taking network beds to ~7,400+ by FY26-end. These additions are concentrated in NCR, Punjab, and Bengaluru—regions with high throughput potential and superior case-mix trends.
ARPOB has increased from ₹49,315 in FY22 to ₹66,301 in FY25 and is projected to reach ₹71,232 by FY28, driven by deeper penetration in oncology, robotic surgeries, neuro, transplants, and other complex care categories.
Occupancy is guided at 70–71% in FY26 (vs. 69% in FY25), with potential to reach 72% by FY28 as new beds ramp up. A strategic shift toward scaling flagship hospitals to 400+ beds is expected to deliver better operating leverage and margin expansion.
Agilus has potentially bottomed out and is entering a margin expansion cycle. EBITDA margins improved from 17.3% in FY24 to 19.8% in FY25, with management guiding toward industry standards (28%) from FY26 onwards.
Growth of 10–11% annually through FY28 is supported by mix normalization, specialty-led offerings, and expansion of the 4,100-touchpoint franchise network. Diagnostics remains a critical incremental earnings lever with improving profitability visibility.
Consolidated EBITDA margins are expected to expand through FY26–FY28, aided by higher occupancies, ARPOB growth, divestment of low-margin assets, and diagnostics recovery. Hospital EBITDA expansion will be supported by operating leverage and a margin-accretive case mix.
Annual capex of ₹800–1,000 crore is fully funded through internal accruals. With robust cash generation and moderated capex beyond FY27, the company is poised to become net debt-free by FY28, improving optionality for brownfield expansion or inorganic acquisitions.
Bajaj Broking Research desk values Fortis Healthcare on an FY28E EV/EBITDA multiple of 26x, arriving at a Target Price of ₹1,051.
The company is entering a multi-year earnings upcycle supported by:
The largest bed expansion program in its history
Rising ARPOB and occupancy levels
Accelerating O&M-led network scaling without incremental capital
Diagnostics margin recovery toward industry standards (~28%)
Removal of regulatory overhang after SEBI’s approval of the IHH open offer
A clear pathway to becoming net debt free by FY28
Particulars | FY26E | FY27E | FY28E |
Revenue (mn) | 95,329 | 1,12,987 | 1,27,472 |
EBITDA (mn) | 21,210 | 25,885 | 30,456 |
PAT (mn) | 11,265 | 15,064 | 18,276 |
EPS | 14.9 | 20.0 | 24.2 |
EBITDA Margin (%) | 22.2 | 22.9 | 23.9 |
PAT Margin (%) | 11.8 | 13.3 | 14.3 |
EV/EBITDA (x) | 34.1 | 27.6 | 23.1 |
P/E (x) | 62.3 | 46.6 | 38.4 |
Debt/Equity | 0.2 | 0.1 | 0.0 |
Category | Q2 FY26 | Q1 FY26 | Q4 FY25 |
Promoter | 31.17% | 31.17% | 31.17% |
FII | 27.90% | 27.18% | 27.40% |
DII | 29.14% | 29.49% | 29.46% |
Others | 11.79% | 11.87% | 11.98% |
Promoter Pledge: 4.78%
Q2 FY26 Revenue: ₹2,331 crore (17.3% YoY)
Q2 FY26 Operating EBITDA: ₹556 crore (28% YoY), margin 23.9%
H1 FY26 Revenue: ₹4,498 crore (16.9% YoY)
H1 FY26 Operating EBITDA: ₹1,047 crore, margin 23.3%
Revenue up 19.3% to ₹1,974 crore
EBITDA margin improved 150 bps to 22.9%
Occupancy: 71% (vs. 69% in Q1)
ARPOB grew 5.8% to ₹2.51 crore per annum
Revenue grew 7.1% to ₹357 crore
EBITDA margin: 26.1% (vs. 21.5%)
Volume impact due to dis-continuation of Aam Aadmi Mohalla Clinic business
Medical Travel revenue up 26% YoY to ₹169 crore
Oncology revenue up 29% YoY
550 beds added in H1 FY26
FY26 organic addition guidance: 400–500 beds
Greater Noida hospital expected to reach ~15% EBITDA in six months
Manesar turned EBITDA-positive within a year
FY27 addition: 300–400 beds driven by FMRI expansion
O&M agreement with Gleneagles
Acquisition of Sriman Superspeciality Hospital
550-bed Lucknow Greenfield O&M signed
Agilus stake at 89%
Net Debt: ₹2,219 crore
Net Debt/EBITDA: 0.96x
Management expects net debt to fall to zero in two years if no major acquisitions occur
Hospital revenue growth of 17–19% expected in H2
Hospital EBITDA margin target of 25% achievable
Diagnostics margin expected at 23–24% for FY26
FMRI 225-bed expansion delayed to Q4 FY26
Fortis Healthcare’s recent performance reflects growth in revenue, operating EBITDA, occupancy, and ARPOB as reported in Q2 FY26 and H1 FY26. The company has added beds across facilities during the period, expanded its O&M portfolio, and completed acquisitions as disclosed. The diagnostics business reported higher EBITDA margins compared to the previous year. The balance sheet shows an increase in net debt due to completed transactions, with a net debt-to-EBITDA ratio of 0.96x as of September 30, 2025. All financial figures, segment performance data, shareholding details, and operational updates in this report are derived from the company’s published information and management commentary included in the source document.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading